Learning Objectives:

  1. Dapagliflozin reduces the risk of kidney failure in patients with CKD but can result in a reversible acute reduction in eGFR on initiation of treatment
  2. DAPA-CKD trial found that patients who experienced an acute reduction in eGFR>10% after 2 weeks of treatment with dapagliflozin had slower rates of long-term eGFR decline compared with patients who experienced a less pronounced decline or increase in eGFR.
  3. A modest acute reduction in eGFR on dapagliflozin initiation is not associated with higher rates of CKD progression and should not be a reason to discontinue this therapy in the majority of patients.


Session date: 
09/23/2022 - 12:00pm to 1:00pm CDT
Via Zoom
5841 S. Maryland Ave
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Tushar Bajaj, MD